A phase II study of high-dose epirubicin plus cisplatinum in advanced non-small-cell lung cancer (NSCLC).

v1

Type:Journal Article

0 views

[![NobleID](https://www.nobleid.org/api/badge/9B5DA69C.svg?ark=w1%2F20260515%2F9B5DA69C)](https://nobleid.org/work/w1/20260515/9B5DA69C)

ARK Inflections

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors